GoAI
Get started
Talphera, Inc. logo

Talphera, Inc.

TLPH

NASDAQHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Regular session

$1.2013

+$0.0113 · +0.95%

Aug 24, 1:17 PM ETData delayed

TLPH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

2

Overpriced

Momentum

76

Gaining

Sentiment

51

Mixed

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
US
CEO
Vincent J. Angotti
Listed since
Feb 11, 2011
Employees
12

Market position

Day range

Current $1.2013

52-week range

Current $1.2013

Open
$1.18
Previous close
$1.19
Volume
45.26K
0.17× average
Average volume
269.33K
Average daily volume
Market cap
62.35M USD
Beta
0.7
Market reference 1
50-day average
$1.2214
-1.65% below average
200-day average
$1.0266
+17.02% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
48.95M USD
P/E (TTM)
-3.76×
P/B (TTM)
6.3×
P/S (TTM)
62,346.99×
EV / EBITDA
-3.41×
Earnings yield
-29.56%
Free cash flow yield
-23.50%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-1474700.00%
Net margin
-1507600.00%
Return on equity
-83.89%
Return on assets
-48.08%
Return on invested capital
-52.04%

Financial health

Debt / equity
0×
Current ratio
5.49×
Altman Z-score
-23.12
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends5214%-15241%-35695%-56149%Gross margin, FY2021: -695.24%Gross margin, FY2023: -751.92%Gross margin, FY2025: 100.00%Operating margin, FY2021: -4792.59%Operating margin, FY2023: -2594.32%Operating margin, FY2025: -48157.14%Net margin, FY2021: -9285.45%Net margin, FY2023: -2825.96%Net margin, FY2025: -51035.71%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -695.24%. Gross margin FY2023 -751.92%. Gross margin FY2025 100.00%. Operating margin FY2021 -4792.59%. Operating margin FY2023 -2594.32%. Operating margin FY2025 -48157.14%. Net margin FY2021 -9285.45%. Net margin FY2023 -2825.96%. Net margin FY2025 -51035.71%.

Income trends

Revenue

28K USD-95.70%

Operating income

−13.48M USD+11.59%

Net income

−14.29M USD-9.89%
Income trends across reported periods50.28M USD19.23M USD−11.81M USD−42.86M USDRevenue, FY2021: 378K USDRevenue, FY2023: 651K USDRevenue, FY2025: 28K USDOperating income, FY2021: −18.12M USDOperating income, FY2022: −20.35M USDOperating income, FY2023: −16.89M USDOperating income, FY2024: −15.25M USDOperating income, FY2025: −13.48M USDNet income, FY2021: −35.1M USDNet income, FY2022: 42.52M USDNet income, FY2023: −18.4M USDNet income, FY2024: −13M USDNet income, FY2025: −14.29M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 378K USD. Revenue FY2023 651K USD. Revenue FY2025 28K USD. Operating income FY2021 −18.12M USD. Operating income FY2022 −20.35M USD. Operating income FY2023 −16.89M USD. Operating income FY2024 −15.25M USD. Operating income FY2025 −13.48M USD. Net income FY2021 −35.1M USD. Net income FY2022 42.52M USD. Net income FY2023 −18.4M USD. Net income FY2024 −13M USD. Net income FY2025 −14.29M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue28K USD—651K USD—378K USD
Cost of goods sold—6.72M USD5.55M USD1.65M USD3.01M USD
Gross profit28K USD−6.72M USD−4.9M USD−1.65M USD−2.63M USD
Research and development6.03M USD6.72M USD5.55M USD1.69M USD2.44M USD
Selling, general, and administrative7.48M USD——17.01M USD—
Operating expenses13.51M USD8.53M USD11.99M USD18.71M USD15.49M USD
Interest income436K USD679K USD6.74M USD1.5M USD3.16M USD
Interest expense—394K USD134K USD1.12M USD2.29M USD
Depreciation and amortization—96K USD96K USD1.65M USD1.97M USD
Operating income−13.48M USD−15.25M USD−16.89M USD−20.35M USD−18.12M USD
Net income−14.29M USD−13M USD−18.4M USD42.52M USD−35.1M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+22.75%
11 comparable reports
Latest EPS result
-0.06
Estimate -0.06 · Beat by 4.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-0.11-0.18-0.25Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.07, estimate -0.21, surprise +66.67%, Beat. Q2 2025, reported May 14, 2025: actual -0.1, estimate -0.17, surprise +41.18%, Beat. Q3 2025, reported Aug 14, 2025: actual -0.1, estimate -0.12, surprise +16.67%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.11, estimate -0.075, surprise -46.67%, Miss. Q1 2026, reported Mar 23, 2026: actual -0.06, estimate -0.075, surprise +20.00%, Beat. Q2 2026, reported May 13, 2026: actual -0.04, estimate -0.07, surprise +42.86%, Beat. Q3 2026, reported Aug 13, 2026: actual -0.06, estimate -0.063, surprise +4.00%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.06, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates626.32K417.83K209.34K850Q1 '24MetQ2 '25No estimateQ4 '25No estimateQ1 '26Estimate
Q1 2024, reported Mar 6, 2024: actual 281K USD, estimate 281K USD, surprise 0.00%, Met estimate. Q2 2025, reported May 14, 2025: actual 27K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual 1K USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 23, 2026: actual —, estimate 580K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$3.00

149.73% upside
Past 12 months12-month forecastHigh $3.00Average $3.00Low $3.00

Recent analyst actions

1 institution

TLPH news

seekingalpha.com

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript

Read source
prnewswire.com

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines…

Read source
prnewswire.com

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in…

Read source

Corporate actions

Corporate action history

Stock split

Effective Oct 26, 2022

1:20

TLPH peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.91

+0.36%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.41

+0.20%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$549.02

+0.18%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$376.28

-0.67%

Sanofi logo

SNY

Sanofi

$45.63

-0.48%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$826.32

-0.93%

ETFs holding TLPH

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
563.33K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.49-0.83%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
335.07K
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.41-0.22%

Continue in GoAI

Research TLPH

research.disclaimer